Amgen and LUMICKS: exploring a new way to understand T-cell engager performance.
Affinity-based models can struggle to capture how strongly T cells and tumor cells actually engage in the presence of a T-cell Engager. Colin Castleberry, Ph.D., Principal Scientist from Amgen and Andrea Candelli, CSO and Co-founder from LUMICKS will present at PEGS Europe 2026 new collaborative research exploring how Cell Avidity could help bridge the gap between molecular affinity, functional assays, and clinical dose-response.
“Towards Validation of Cell Avidity as a Critical Assay for Improving Human Dose–response Prediction and Preclinical Screening of T-cell Engagers Therapies“
Poster A066, Tuesday November 17, Lisbon Portugal
The study examines Cell Avidity across T-cell engagers and connects it to affinity tuning, antigen density, functional responses, and clinical exposure-response, with the goal of generating quantitative parameters that can inform QSP models.
Top three things to discover at our poster:
- See why molecular affinity alone may not capture how T-cell engagers drive cell-cell engagement.
- Discover how Cell Avidity measurements may relate to downstream functional responses measured in vitro.
- Explore how Cell Avidity is being explored as a potential input for QSP modeling and may inform clinical exposure-response prediction.
Meet the team next week at PEGS and explore the data!
.png)
.jpg)